title: Aliskiren (Speedel).
abstract: Speedel Pharma is developing aliskiren (formerly CGP-60536), a renin inhibitor under license from Novartis, for the potential treatment of several cardiovascular disorders. By October 2001, a phase IIb study in hypertension had been completed, and phase III studies for this indication were anticipated for 2002; at this time, phase II studies in congestive heart failure and chronic renal failure were ongoing.
authors.affiliation: University of Tartu, Department of Cardiology, Estonia. Kristina.Allikmets@kliinikum.ee
authors.forename: Kristina
authors.initials: K
authors.lastname: Allikmets
mesh_terms: D000577:Amides; D000818:Animals; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005650:Fumarates / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D006801:Humans; D000092502:Renin Inhibitors
chemical_list: D000577:Amides; D000959:Antihypertensive Agents; D005650:Fumarates; D000092502:Renin Inhibitors; C446481:aliskiren